Management of actinic keratosis: A practical report and treatment algorithm from AKTeam™ expert clinicians

Journal of the European Academy of Dermatology and Venereology

Volumn 28, Issue 9, 2014, Pages 1141-1149

  Dreno B ^a   Amici, J M ^b,c   Basset Seguin, N ^d   Cribier, B ^e   Claudel, J P ^f,g   Richard, M A ^h  

^a HÔTEL DIEU   (France)

^b Cabinet de Dermatologie Rive Droite   (France)

^c HÔPITAL SAINT ANDRÉ   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^f Cabinet de Dermatologie   (France)

^g Centre de Pediatrie Clocheville   (France)

^h AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COSMETIC; DEOXYRIBODIPYRIMIDINE PHOTOLYASE; DICLOFENAC; FLUOROURACIL; IMIQUIMOD; INGENOL MEBUTATE; SALICYLIC ACID;

ACTINIC KERATOSIS; ALGORITHM; APPLICATION SITE EDEMA; APPLICATION SITE ERYTHEMA; APPLICATION SITE PAIN; APPLICATION SITE PRURITUS; APPLICATION SITE PUSTULE; APPLICATION SITE RASH; APPLICATION SITE ULCER; APPLICATION SITE VESICLE; BURNING SENSATION; CLINICAL EVALUATION; CLINICAL PRACTICE; CONTACT DERMATITIS; CRYOTHERAPY; DERMATOLOGIST; DRY SKIN; ELECTROCOAGULATION; EROSION; FATIGUE; FRANCE; HUMAN; HYPERPIGMENTATION; LOW LEVEL LASER THERAPY; MEDICAL LITERATURE; MYALGIA; NAUSEA; NOMENCLATURE; ORGAN TRANSPLANTATION; PHOTODYNAMIC THERAPY; PHYSIOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SKIN BIOPSY; SKIN SURGERY; SKIN ULCER; THERAPY EFFECT; TOPICAL TREATMENT; TREATMENT INDICATION; KERATOSIS, ACTINIC;

ALGORITHMS; HUMANS; KERATOSIS, ACTINIC; TERMINOLOGY AS TOPIC;

EID: 84906935599     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12434     Document Type: Review

References (68)

1. Memon AA, Tomenson JA, Bothwell J, Friedmann PS,. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol 2000; 142: 1154-1159.
2. Frost CA, Green AC,. Epidemiology of solar keratoses. Br J Dermatol 1994; 131: 455-464.
3. Harvey I, Frankel S, Marks R, Shalom D, Nolan-Farrell M,. Non-melanoma skin cancer and solar keratoses II analytical results of the South Wales Skin Cancer Study. Br J Cancer 1996; 74: 1308-1312.
4. Bickers DR, Lim HW, Margolis D, et al,. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol 2006; 55: 490-500.
5. Green A, Battistutta D,. Incidence and determinants of skin cancer in a high-risk Australian population. Int J Cancer 1990; 46: 356-361.
6. Salasche SJ,. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000; 42: 4-7.
7. Bernard P, Dupuy A, Sasco A, et al,. Basal cell carcinomas and actinic keratoses seen in dermatological practice in France: a cross-sectional Survey. Dermatology 2008; 216: 194-199.
8. Martin L, Bonerandi JJ,. Carcinome épidermoïde cutané (carcinome spinocellulaire): recommandations de pratique clinique pour la prise en charge diagnostique et thérapeutique. Rapport intégral. Ann Dermatol Venereol 2009; 136: S189-S242.
9. Haute AS,. Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinome and precursor lesions. Guidelines. Rev Stomatol Chir Maxillofac 2010; 111: 228-237.
10. Bonerandi JJ, Beauvillain C, Caquant L, et al,. Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma and precursor lesions. J Eur Acad Dermatol Venereol 2011; 25: 1-51.
11. Drake LA, Ceilley RI, Cornelison RL, et al,. Guidelines of care for actinic keratoses. Committee on Guidelines of Care. J Am Acad Dermatol 1995; 32: 95-98.
12. de Berker D, McGregor JM, Hughes BR,; British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for the management of actinic keratoses. Br J Dermatol 2007; 156: 222-230.
13. Rossi R, Calzavara-Pinton PG, Giannetti A, et al,. Italian guidelines and therapeutic algorithm for actinic keratoses. G Ital Dermatol Venereol 2009; 144: 713-723.
14. Stockfleth E, Kerl H,. Guidelines for the management of actinic keratoses. Eur J Dermatol 2006; 16: 599-606.
15. Stockfleth E, Ferrandiz C, Grob JJ, Leigh I, Pehamberger H, Kerl H,; European Skin Academy. Development of a treatment algorithm for actinic keratoses: a European Consensus. Eur J Dermatol 2008; 18: 651-659.
16. Nashan D, Meiss F, Müller M,. Therapeutic strategies for actinic keratoses-a systematic review. Eur J Dermatol 2013; 23: 14-32.
17. Lansbury L, Leonardi-Bee J, Perkins W, Goodacre T, Tweed JA, Bath-Hextall FJ,. Interventions for non-metastatic squamous cell carcinoma of the skin. Cochrane Database Syst Rev 2010; CD007869.
18. Gupta AK, Inniss K, Wainwright R, Chow M, Cooper E,. Interventions for actinic keratoses (Protocol). Cochrane Database Syst Rev 2003; CD004415.
19. Ackerman AB, Mones JM,. Solar (actinic) keratosis is squamous cell carcinoma. Br J Dermatol 2006; 155: 9-22.
20. Marks R, Foley P, Goodman G, Hage BH, Selwood TS,. Spontaneous clearance of solar keratoses: the case for conservative management. Br J Dermatol 1986; 115: 649-655.
21. Frost C, Williams G, Green A,. High incidence and regression rates of solar keratoses in a Queensland community. J Invest Dermatol 2000; 115: 273-277.
22. Dodson JM, DeSpain J, Hewett JE, Clark DP,. Malignant potential of actinic keratoses and the controversy over treatment. A patient-oriented perspective. Arch Dermatol 1991; 127: 1029-1031.
23. Feldman SR, Fleischer AB Jr,. Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications. Cutis 2011; 87: 201-207.
24. Marks R, Rennie G, Selwood TS,. Malignant transformation of solar keratoses to squamous carcinoma. Lancet 1988; 1: 795-797.
25. Mittelbronn MA, Mullins DL, Ramos-Caro FA, Flowers FP,. Frequency of pre-existing actinic keratosis in cutaneous squamous cell carcinoma. Int J Dermatol 1998; 37: 677-681.
26. Marks R, Rennie G, Selwood T,. The relationship of basal cell carcinomas and squamous cell carcinomas to solar keratoses. Arch Dermatol 1988; 124: 1039-1042.
27. Kanjilal S, Strom SS, Clayman GL, et al,. p53 mutations in nonmelanoma skin cancer of the head and neck: molecular evidence for field cancerization. Cancer Res 1995; 55: 3604-3609.
28. Szeimies RM, Torezan L, Niwa A, et al,. Clinical, histopathological and immunohistochemical assessment of human skin field cancerization before and after photodynamic therapy. Br J Dermatol 2012; 167: 150-159.
29. Quaedvlieg PJ, Tirsi E, Thissen MR, Krekels GA,. Actinic keratosis. How to differentiate the good and the bad ones? Eur J Dermatol 2006; 16: 335-339.
30. Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E,. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol 2007; 157: 34-40.
31. Freeman M, Vinciullo C, Francis D, et al,. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatolog Treat 2003; 14: 99-106.
32. Szeimies RM, Karrer S, Radakovic-Fijan S, et al,. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol 2002; 47: 258-262.
33. Morton C, Campbell S, Gupta G, et al,. Intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. Br J Dermatol 2006; 155: 1029-1036.
34. Kaufmann R, Spelman L, Weightman W, et al,. Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities. Br J Dermatol 2008; 158: 994-999.
35. Prens SP, Vries KD, Neumann HA, Prens EP,. Non-ablative fractional resurfacing in combination with topical tretinoin cream as a field treatment modality for multiple actinic keratosis: a pilot study and review of other field treatment modalities. J Dermatolog Treat 2013; 24: 227-231.
36. Torgsverd-Bo K, Haak CS, Thaysen-Petersen D, Wulf HC, Anderson RR, Haedesdal M,. Intensified photodynamic therapy of actinic keratoses with fractional CO2 laser: a randomized clinical trial. Br J Dermatol 2012; 166: 1262-1269.
37. Katz TM, Goldberg LH, Marquez D, et al,. Nonablative fractional photothermolysis for facial actinic keratoses: 6 month follow-up with histologic evaluation. J Am Acad Dermatol 2011; 65: 349-356.
38. Résumé des caractéristiques du produit, Metvixia®, VIDAL 2012.
39. Braathen LR, Morton CA, Basset-Seguin N, et al,. Photodynamic therapy for skin field cancerization: an international consensus. International Society for Photodynamic Therapy in Dermatology. J Eur Acad Dermatol Venereol 2012; 26: 1063-1066.
40. Morton CA, Szeimies RM, Sidoroff A, Braathen LR,. European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications-actinic keratoses, Bowen's disease, basal cell carcinoma. J Eur Acad Dermatol Venereol 2013; 27: 536-544.
41. Pariser D, Loss R, Jarratt M, et al,. Topical methyl-aminolevulinate photodynamic therapy using red light-emitting diode light for treatment of multiple actinic keratoses: a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 2008; 59: 569-576.
42. Pariser DM, Lowe NJ, Stewart DM, et al,. Photodynamic therapy with topical methyl aminolevulinate for actinickeratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol 2003; 48: 227-232.
43. Braathen LR, Paredes BE, Saksela O, et al,. Short incubation with methyl aminolevulinate for photodynamic therapy of actinic keratoses. J Eur Acad Dermatol Venereol 2009; 23: 550-555.
44. Wiegell SR, Wulf HC, Szeimies RM, et al,. Daylight photodynamic therapy for actinic keratosis: an international consensus: International Society for Photodynamic Therapy in Dermatology. J Eur Acad Dermatol Venereol 2012; 26: 673-679.
45. Olsen EA, Abernethy ML, Kulp-Shorten C, et al,. A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol 1991; 24: 738-743.
46. Rivers JK, Arlette J, Shear N, Guenther L, Carey W, Poulin Y,. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 2002; 146: 94-100.
47. Stege H,. Effect of xenogenic repair enzymes on photoimmunology and photocarcinogenesis. J Photochem Photobiol, B 2001; 65: 105-108.
48. Résumé des caractéristiques du produit, Efudix®, VIDAL 2012.
49. Tanghetti E, Werschler P,. Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp. J Drugs Dermatol 2007; 6: 144-147.
50. Loven K, Stein L, Furst K, Levy S,. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther 2002; 24: 990-1000.
51. Résumé des caractéristiques du produit, Aldara®, VIDAL 2012.
52. Jorizzo JL, Markowitz O, Lebwohl MG, et al,. A randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratoses. J Drugs Dermatol 2010; 9: 1101-1108.
53. Lebwohl M, Dinehart S, Whiting D, et al,. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004; 50: 714-721.
54. Szeimies RM, Gerritsen MJ, Gupta G, et al,. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol 2004; 51: 547-555.
55. Korman N, Moy R, Ling M, et al,. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol 2005; 141: 467-473.
56. Jorizzo J, Dinehart S, Matheson R, et al,. Vehicle-controlled, doubled-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol 2007; 57: 265-268.
57. Alomar A, Bichel J, McRae S,. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol 2007; 157: 133-141.
58. Résumé des caractéristiques du produit, Solaraze®, VIDAL 2012.
59. Wolf JE Jr, Taylor JR, Tschen E, Kang S,. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 2001; 40: 709-713.
60. Résumé des caractéristiques du produit, Picato®, extract from EPAR 29 November 2012 (EMA Website).
61. Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B,. Ingenol mebutate for actinic keratoses. N Engl J Med 2012; 366: 1010-1019.
62. O'Reilly Zwald F, Brown M,. Skin cancer in solid organ transplant recipients: advances in therapy and management. Part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011; 65: 253-261.
63. O'Reilly Zwald F, Brown M,. Skin cancer in solid organ transplant recipients: advances in therapy and management. Part II. Management of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011; 65: 263-279.
64. Robinson JK, Turrisi R, Mallett KA, et al,. Efficacy of an educational intervention with kidney transplant recipients to promote skin self-examination for squamous cell carcinoma detection. Arch Dermatol 2011; 147: 689-695.
65. Uhlenhake EE,. Optimal treatment of actinic keratoses. Clin Interv Aging 2013; 8: 29-35.
66. Ceilley RI, Jorizzo JL,. Current issues in the management of actinic keratosis. J Am Acad Dermatol 2013; 68: S28-S38.
67. Ulrich C, Jürgensen JS, Degen A, et al,. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol 2009; 161: 78-84.
68. Sambandan DR, Ratner D,. Sunscreens: an overview and update. J Am Acad Dermatol 2011; 64: 748-758.